Product Information
ASPIRIN-DIPYRIDAM ER 25-200 MG is a generic product labeled by Endo USA Inc., priced at $0.5586 per EA under NDC 49884000702. Its NADAC has been published 404 times since Jan 9, 2019.
FDA first approved this application on Jan 18, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
25; 200 mg/1; mg/1
Manufacturer
Endo USA Inc.NDC
49884000702
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ASPIRIN; DIPYRIDAMOLEApproval Type
Generic (ANDA)
FDA Application
ANDA207944FDA Approved
1/18/2017
TE Code
AB
On Market Since
1/30/2017
Pharmacological Classes
Price Statistics
The NADAC for ASPIRIN-DIPYRIDAM ER 25-200 MG has been published 404 times since Jan 9, 2019, and over the history we have for it it has declined 87.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.5586 per EA |
|---|---|
| All-time high | $4.4460 (Feb 13, 2019) |
| All-time low | $0.5561 (Mar 18, 2026) |
| 52-week high | $0.6072 |
| 52-week low | $0.5561 |
| Median price | $0.8034 |
| Average price | $1.2760 |
| Largest weekly change | +44.2% (Apr 21, 2021) |
| Weeks tracked | 404 |
| Tracking since | Jan 9, 2019 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Endo USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Aspirin and Extended - Release Dipyridamole market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ASPIRIN-DIPYRIDAM ER 25-200 MG?
The current National Average Drug Acquisition Cost (NADAC) for ASPIRIN-DIPYRIDAM ER 25-200 MG, manufactured by Endo USA Inc., is $0.5586 per EA (NDC 49884000702), effective Sep 30, 2026.
How has the price of ASPIRIN-DIPYRIDAM ER 25-200 MG changed over time?
Over the history we have for it, the NADAC for ASPIRIN-DIPYRIDAM ER 25-200 MG has declined 87.1%. It has been tracked across 404 weekly CMS publications since Jan 9, 2019.
What are the highest and lowest recorded NADAC prices for ASPIRIN-DIPYRIDAM ER 25-200 MG?
Since Jan 9, 2019, the NADAC for ASPIRIN-DIPYRIDAM ER 25-200 MG has ranged from a low of $0.5561 (Mar 18, 2026) to a high of $4.4460 (Feb 13, 2019), with a median of $0.8034 per EA.
Are there cheaper alternatives to ASPIRIN-DIPYRIDAM ER 25-200 MG?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as ASPIRIN-DIPYRIDAM ER 25-200 MG in a comparable dosage form, but none are currently priced below it.
Who manufactures ASPIRIN-DIPYRIDAM ER 25-200 MG?
ASPIRIN-DIPYRIDAM ER 25-200 MG (NDC 49884000702) is labeled by Endo USA Inc., and CMS classifies it as a generic product.